MSICS Pharma, a pioneer in Israel's naturally-sourced Psilocybin production for pharmaceutical use, proudly holds groundbreaking Psilocybin operational licenses. Our innovative GMP production facility is already hard at work, and we're currently navigating a unique approval process, drawing from our successful experience with Cannabis.

Our Psilocybin products are now poised for first-of-a-kind clinical trials with esteemed hospitals, to treat conditions like OCD, Anorexia, PTSD, and depression at first, all within a market valued in the billions of dollars.

We are on track to approve our products as prescribed medicine through a distinctive approval process beginning in Israel, serving as the ideal pharmaceutical beta-site, and extending globally to address unmet medical needs.